


# METABOLIC SYNDROME AND NEUROLOGICAL DISORDERS

*Edited by*  
**Tahira Farooqui and Akhlaq A. Farooqui**



**Heart Disease**

**Dementia**

**Stroke**

**Metabolic  
Syndrome**

**Alzheimer  
Disease**

**Depression**

**Parkinson  
Disease**

**WILEY** Blackwell



# **METABOLIC SYNDROME AND NEUROLOGICAL DISORDERS**



# **METABOLIC SYNDROME AND NEUROLOGICAL DISORDERS**

---

**Edited by**

**TAHIRA FAROOQUI AND AKHLAQ A. FAROOQUI**

**WILEY** Blackwell

This edition first published 2013 © 2013 by John Wiley & Sons, Inc.

*Editorial offices:* 2121 State Avenue, Ames, Iowa 50014-8300, USA  
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK  
9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com/wiley-blackwell](http://www.wiley.com/wiley-blackwell).

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Publishing, provided that the base fee is paid directly to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license by CCC, a separate system of payments has been arranged. The fee codes for users of the Transactional Reporting Service are ISBN-13: 978-1-1183-9527-1/2013.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author(s) have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. It is sold on the understanding that the publisher is not engaged in rendering professional services and neither the publisher nor the author shall be liable for damages arising herefrom. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

*Library of Congress Cataloging-in-Publication Data*

Metabolic syndrome and neurological disorders / Tahira Farooqui and Akhlaq A. Farooqui, editors.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-118-39527-1 (cloth : alk. paper) – ISBN 978-1-118-39528-8 (Epub) – ISBN 978-1-118-39529-5 (Epdf) –

ISBN 978-1-118-39530-1 (Emobi) – ISBN 978-1-118-39531-8 (ebook)

I. Farooqui, Tahira, editor of compilation. II. Farooqui, Akhlaq A., editor of compilation.

[DNLM: 1. Metabolic Syndrome X—etiology. 2. Metabolic Syndrome X—metabolism. 3. Nervous System Diseases—etiology.

4. Nervous System Diseases—metabolism. WK 820]

RC629

616.3'99—dc23

2013029484

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover image: body image © angelhell

Cover design by Nicole Teut

Set in 10/12pt Times by Aptara® Inc., New Delhi, India

*Dedicated to our late parents  
For their unconditional love, support and understanding.*

*“Every human being is the author of his own health or disease.”*

Siddhārtha Gautama Buddha



# CONTENTS

<b>Foreword</b>	<i>Mark P. Mattson</i>	<b>xi</b>
<b>Preface</b>	<i>Tahira Farooqui and Akhlaq A. Farooqui</i>	<b>xiii</b>
<b>Acknowledgments</b>	<i>Tahira Farooqui and Akhlaq A. Farooqui</i>	<b>xv</b>
<b>Contributors</b>		<b>xvii</b>
<b>1</b>	<b>Insulin Resistance and Metabolic Failure Underlie Alzheimer Disease</b> <i>Suzanne M. de la Monte and Ming Tong</i>	<b>1</b>
<b>2</b>	<b>Insulin Receptor and the Pathophysiology of Alzheimer Disease</b> <i>Johanna Zemva and Markus Schubert</i>	<b>31</b>
<b>3</b>	<b>Contribution of Insulin Resistance in Pathogenesis of Alzheimer Disease</b> <i>Adnan Erol</i>	<b>51</b>
<b>4</b>	<b>Insulin–Leptin Signaling in the Brain</b> <i>Vicente Barrios, Emma Burgos-Ramos, and Jesús Argente</i>	<b>75</b>
<b>5</b>	<b>The Janus Face of Insulin in Brain</b> <i>Ana Duarte, Emanuel Candeias, Sónia C. Correia, Renato X. Santos, Cristina Carvalho, Susana Cardoso, Ana I. Plácido, Maria S. Santos, Catarina R. Oliveira, and Paula I. Moreira</i>	<b>85</b>
<b>6</b>	<b>Modulation of Cognition by Insulin and Aging: Implications for Alzheimer Disease</b> <i>Maite Solas and Maria J. Ramírez</i>	<b>115</b>

<b>7</b>	<b>Contribution of Phospholipid, Sphingolipids, and Cholesterol-Derived Lipid Mediators in the Pathogenesis of Metabolic Syndrome and Neurological Disorders</b>	<b>137</b>
	<i>Akhlaq A. Farooqui and Tahira Farooqui</i>	
<b>8</b>	<b>Lipids, Cholesterol, and Oxidized Cholesterol in Alzheimer Amyloid Beta-Mediated Neurotoxicity</b>	<b>163</b>
	<i>Mun'delanji C. Vestergaard, Masamune Morita, Tsutomu Hamada, and Masahiro Takagi</i>	
<b>9</b>	<b>Of Sound Mind and Body: Dietary Lifestyles, Promotion of Healthy Brain Aging, and Prevention of Dementia in Healthy Individuals</b>	<b>179</b>
	<i>Giulio Maria Pasinetti, Amanda Bilski, Lap Ho, Jun Wang, Mario Ferruzzi, Masahito Yamada, Kenjiro Ono, and Salvatore Mannino</i>	
<b>10</b>	<b>Metabolic Syndrome as an Independent Risk Factor of Silent Brain Infarction</b>	<b>191</b>
	<i>Jae-Sung Lim and Hyung-Min Kwon</i>	
<b>11</b>	<b>Neurochemical Linkage Among Metabolic Syndrome, Alzheimer Disease, and Depression</b>	<b>197</b>
	<i>Undurti N. Das</i>	
<b>12</b>	<b>Alterations in the Endocannabinoid System as a Link Between Unbalanced Energy Homeostasis, Neuroinflammation, and Neurological and Neuropsychiatric Disorders</b>	<b>219</b>
	<i>Tiziana Bisogno and Vincenzo Di Marzo</i>	
<b>13</b>	<b>Metabolic Syndrome, Alzheimer Disease, Schizophrenia, and Depression: Role for Leptin, Melatonin, Kynurenine Pathways, and Neuropeptides</b>	<b>235</b>
	<i>George Anderson and Michael Maes</i>	
<b>14</b>	<b>Binge Eating and Metabolic Syndrome</b>	<b>249</b>
	<i>Ignacio Jáuregui-Lobera</i>	
<b>15</b>	<b>Phytochemical Principles in the Traditional Indian System of Medicine Used for the Management of Metabolic Syndrome</b>	<b>261</b>
	<i>Syed Ibrahim Rizvi and Neetu Mishra</i>	
<b>16</b>	<b>Oxidative Stress and Obesity: Their Impact on Metabolic Syndrome</b>	<b>275</b>
	<i>Morihiro Matsuda and Iichiro Shimomura</i>	
<b>17</b>	<b>The Relationship Among Obesity, Inflammation, and Insulin Resistance</b>	<b>283</b>
	<i>Jean-Philippe Bastard and Bruno Fève</i>	
<b>18</b>	<b>Involvement of Adipocytokines in Pathogenesis of Insulin Resistance, Obesity, and Metabolic Syndrome</b>	<b>297</b>
	<i>Hardik Gandhi and Ramachandran Balaraman</i>	
<b>19</b>	<b>Obesity, Inflammation, and Vascular Disease: Novel Insight in the Role of Adipose Tissue</b>	<b>311</b>
	<i>Paolo Calabro, Enrica Golia, Valeria Maddaloni, Giuseppe Limongelli, Brunella Ziello, Fabio Fimiani, Ilaria Jane Romano, Mario Crisci, Maria Giovanna Russo, Edward T.H. Yeh, and Raffaele Calabro</i>	

<b>20</b>	<b>Is Diabetes a Risk Factor for Parkinson Disease?</b>	<b>327</b>
	<i>Akhlaq A. Farooqui and Tahira Farooqui</i>	
<b>21</b>	<b>Role of Iron in the Pathogenesis of Diabetes and Metabolic Syndrome</b>	<b>335</b>
	<i>Lu Cai</i>	
<b>22</b>	<b>Contributions of AMP Kinase to the Pathogenesis of Type 2 Diabetes and Neurodegenerative Diseases</b>	<b>363</b>
	<i>Mohamed Kodiha, Hicham Mahboubi, and Ursula Stochaj</i>	
<b>23</b>	<b>A<math>\beta</math> Deposition, Insulin Signaling, and Tau Phosphorylation in Animal Models of Alzheimer Disease and Diabetes</b>	<b>383</b>
	<i>Naoyuki Sato and Ryuichi Morishita</i>	
<b>24</b>	<b><i>In Vivo</i> Evidence of the Convergence of Type 2 Diabetes and Alzheimer Disease</b>	<b>395</b>
	<i>Sun Ah Park</i>	
<b>25</b>	<b>Metabolic Syndrome and its Impact on Cardiovascular Disease</b>	<b>409</b>
	<i>John A. Larry</i>	
<b>26</b>	<b>Contribution of Inflammation, Adiponectin, and Obesity in Cardiovascular Diseases</b>	<b>423</b>
	<i>Harald Mangge and Gunter Almer</i>	
<b>27</b>	<b>Brain and Cardiovascular Diseases: Molecular Aspects</b>	<b>439</b>
	<i>Ewa Szczepanska-Sadowska</i>	
<b>28</b>	<b>Molecular Aspects of Dietary–Exercise Regimen for the Prevention of Metabolic Syndrome</b>	<b>461</b>
	<i>Wataru Aoi</i>	
<b>29</b>	<b>Ghrelin, Lipid Metabolism, and Metabolic Syndrome</b>	<b>475</b>
	<i>Pablo B. Martínez de Morentin, Sulay Tovar, Rubén Nogueiras, Miguel López, and Carlos Diéguez</i>	
<b>30</b>	<b>Leptin and Cognitive Function</b>	<b>485</b>
	<i>Jenni Harvey</i>	
<b>31</b>	<b>Fructose, Sugar Consumption, and Metabolic Diseases</b>	<b>501</b>
	<i>Virgile Lecoultrre and Luc Tappy</i>	
<b>32</b>	<b>Inflammation-Mediated Cognitive and Emotional Alterations in Experimental Models of Metabolic Syndrome</b>	<b>515</b>
	<i>Nathalie Castanon and Sophie Layé</i>	
<b>33</b>	<b>Summary and Perspective</b>	<b>529</b>
	<i>Tahira Farooqui and Akhlaq A. Farooqui</i>	
	<b>Index</b>	<b>539</b>

Color plate section is located between pages 196 and 197.



# FOREWORD

Metabolic syndrome (MetS) is a pathologic state that most often results from a chronic positive energy balance due to an excessive energy intake (particularly refined sugars and saturated and trans fats) and a sedentary lifestyle. The defining clinical features of MetS are insulin resistance, central obesity, dyslipidemia, and hypertension. It was established several decades ago that MetS is prodromal to diabetes and that individuals with MetS have a high risk of myocardial infarction and stroke. However, within the past ten years it has become clear that MetS adversely affects brain structure and function and is a risk factor for Alzheimer disease (AD) and stroke. In *Metabolic Syndrome and Neurological Disorders* Tahira and Akhlaq Farooqui have drawn upon the knowledge of experts in the fields of neuroscience, neurology, endocrinology, cardiovascular disease, obesity, and diabetes to compile a timely review of the impact of MetS on the brain and its vulnerability to neurological disorders. This is a critically important area of research for four major reasons: (1) there is an ongoing epidemic of overweight, obesity, and MetS in modern societies; (2) due to advances in the early diagnosis and treatment of cancers and cardiovascular disease, large numbers of individuals are reaching their seventh, eighth, and ninth decades of life, the “danger zones” for AD and stroke; (3) there are no effective drugs to counteract the neuronal damage

that occurs in AD and stroke; and (4) AD patients and stroke patients often require a decade or more of constant care, and therefore place a greater personal and economic burden on society than many other major diseases. Although less profound, emerging evidence also suggests that, in addition to AD and stroke, the MetS may predispose to a broader range of neurological disorders including Parkinson disease, depression, and possibly schizophrenia.

Because of its adverse effects on essentially all organ systems including the brain, an understanding of the molecular and cellular alterations that cause the MetS, and the mechanisms by which the MetS promotes dysfunction and degeneration of brain cells, will be required to develop novel approaches for preventing and treating MS and associated diseases. As detailed in *Metabolic Syndrome and Neurological Disorders*, alterations resulting from a chronic positive energy balance that are involved in the genesis of the MetS include oxidative stress and inflammation and associated dysregulation of lipid (sphingolipids, cholesterol, and others) metabolism. As a result, signaling pathways that normally protect brain cells and promote their optimal functionality are impaired, including pathways activated by the hormones insulin, leptin, adiponectin, and brain-derived neurotrophic factor (BDNF). In addition, oxidative stress, inflammation, and abnormal lipid metabolism

can increase the production and/or reduce the removal of the neurotoxic amyloid beta-peptide, which likely contributes to the dysfunction and degeneration of neurons in AD. With regards to the pathogenesis of stroke, hypertension, dyslipidemia, and local oxidative stress and inflammation in cerebral blood vessels result in a narrowing and weakening of the vessels.

The good news for those with motivation is that the MetS can be effectively prevented and treated by adherence to prescriptions for exercise and dietary energy restriction. Exercise and energy restriction (particularly intermittent fasting) can prevent or reverse MetS by enhancing insulin sensitivity, increasing utilization of fats, stimulating antioxidant and anti-inflammatory pathways, and enhancing parasympathetic tone, which decreases blood pressure. Recent findings from animal research, and epidemiological and clinical studies, suggest that AD and stroke may also be prevented or delayed by regular exercise and moderation in energy intake during adult life. In addition to protecting the brain by reversing all of the peripheral manifestations of the MetS, exercise and energy restriction have been shown to have direct effects on brain cells that optimize brain function and may forestall AD and stroke. These include increased production of neurotrophic factors, improved cellular bioenergetics, and reduced oxidative stress.

For those unwilling or unable to exercise regularly and restrict their calorie intake so as to maintain a

normal body weight *Metabolic Syndrome and Neurological Disorders* reviews potential dietary and drug interventions that are being developed and tested in clinical studies. As with research toward understanding disease mechanisms, translational research for MetS and neurodegenerative disorders is accelerated by the use of animal models. Studies of animal models of AD and stroke have demonstrated beneficial effects of insulin, leptin, incretin peptides such as glucagon-like peptide 1 analogs, and PPAR- $\gamma$  agonists that are insulin-sensitizing agents such as metformin and rosiglitazone. Many of these drugs are now in clinical trials in patients with mild cognitive impairment or early AD. Targeting lipid metabolism is also being pursued via studies of dietary supplementation with omega-3 fatty acids or the use of cholesterol-lowering drugs. Other approaches that might prove beneficial for protecting the brain in subjects with MetS include drugs that suppress appetite, such as cannabinoid receptor antagonists. This book will provide a valuable resource to guide future research projects to disentangle the complex cellular and molecular underpinnings of MetS-related neuropathologies, and to thereby inform the development of novel therapeutic interventions for neurological disorders.

MARK P. MATTSON

*National Institute on Aging  
Intramural Research Program  
Baltimore, MD*

# PREFACE

At the end of 2011, the United Nations declared for the first time in the history of humanity that non-communicable diseases had outpaced infectious diseases as the main global threat to human health. Among non-communicable diseases, metabolic syndrome (MetS), cardiovascular diseases, and Alzheimer disease (AD) are of paramount importance. MetS is a condition characterized by clustering of insulin resistance, hyperinsulinemia, hypertension, dyslipidemia, impaired glucose disposal, type 2 diabetes, abnormal blood fat levels, fatty liver disease, and abdominal obesity. Changes in human dietary habits in recent decades have led to the consumption of hypercaloric diets that are rich in saturated fats and simple sugars (sucrose, glucose, and fructose). The MetS is a highly prevalent pathological condition that affects a considerable number of adult humans. Approximately one-fourth of European, American, and Canadian adults suffer from MetS. Clustering of insulin resistance, hyperinsulinemia, hypertension, dyslipidemia, impaired glucose disposal, type 2 diabetes, and abdominal obesity reflects overnutrition, sedentary lifestyles, physical inactivity, and resultant excess adiposity. At the molecular level, MetS is accompanied not only by dysregulation in the expression of adipocytokines and chemokines, but also by increase in levels of lipids and lipid mediators (free fatty acids, di- and triacylglycerols,

and ceramide). These changes modulate immune response and inflammation that lead to alterations in the hypothalamic body-weight/appetite/satiety set point, resulting in the initiation and development of MetS.

MetS is a risk factor for neurological disorders such as stroke, depression, and AD. The molecular mechanism underlying the relationship between MetS and neurological disorders is not fully understood. However, major mechanisms through which MetS may influence stroke, AD, and depression include insulin resistance, impairment in insulin receptor, and insulin growth factor signaling, glucose toxicity, elevated levels of phospholipid-, sphingolipid-, and cholesterol-derived lipid mediators, generation of advanced glycation endproducts, activation of receptor for advanced glycation endproducts, cerebrovascular injury, and vascular inflammation that may represent a pathological bridge between MetS and neurological disorders such as stroke, AD, and depression.

Information on molecular links between MetS and neurological disorders is scattered throughout the literature mainly in the form of original papers and some reviews. Although, many books are published on biochemistry of MetS and neurological disorders separately, at present there are no books on the relationship between MetS and neurological disorders.